Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03671889 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT03671889 · ClinicalTrials.gov record · last posted 2026-01-09

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

StatusRecruiting
PhaseNot applicable
SponsorInSightec
Started2018-09-28
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

Amendment record 25 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 25 times since 2018-09-12; most recent amendment 2026-01-08. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2018-10-17
Status change Not Yet Recruiting→Recruitingv2
Trial Details
NCT Number NCT03671889
Lead Sponsor InSightec
Conditions Alzheimer Disease
Enrollment 50 participants
Start Date 2018-09-28
Primary Completion 2028-01 (estimated)
Study Completion 2030-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-09